Phase 2 study of pelacarsen andcalcific aortic valve stenosis (NCT05646381, Ongoing)

To evaluate the efficacy, safety and tolerability of pelacarsen administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis (CAVS)